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Plasma Ceruloplasmin, a Regulator of Nitric Oxide
Activity, and Incident Cardiovascular Risk in Patients
with CKD
David J. Kennedy, Yiying Fan,Yuping Wu, Michael Pepoy  Stanley L. Hazen, and W.H. Wilson Tang

Abstract
BackgroundandobjectivesIncreasedserumlevelsoftheacute-phasereactantceruloplasminpredictadverse
clinicaloutcomesinthesettingofacutecoronarysyndromesandheartfailure,buttheirroleinpatientswithCKD
isunclear.ThisstudyinvestigatedtherelationshipofceruloplasminwithclinicaloutcomesinCKD,especially
withregardtotraditionalcardiacbiomarkers.
Design,setting,participants,&measurementsSerumceruloplasminlevelsinconsecutivestudyparticipantswith
CKD(n=654;estimatedGFR,60ml/minper1.73m2)aswellasacontrolgroupofnon-CKDparticipants
matchedforageandsex(n=250)weremeasured.Studyparticipantswereenrolledduring2001 2006froma
populationofpatientspresentingforelectivediagnosticcoronaryangiographyandprospectivelyfollowedfor
3years(medianfollow-up=1095days)todetermineincidentmajoradversecardiacevents(deﬁnedasa
compositeofdeath,nonfatalmyocardialinfarction,andstroke).
ResultsSerumceruloplasminlevelsinCKDpatientswereelevatedversuscontrols(median[interquartilerange];
25.5[21.8 29.6]versus22.7[19.7 26.5]mg/dl;P,0.001)andassociatedwithincreasedriskoffuturemajor
adversecardiacevents(hazardratio,1.35;95%conﬁdenceinterval,1.0to1.82;P=0.04).Afteradjustingfor
traditionalriskfactors,higherserumceruloplasminwasstillassociatedwithhigherriskofmajoradversecardiac
eventsat3years(hazardratio,1.61;95%conﬁdenceinterval,1.15to2.25;P=0.01).
ConclusionInCKDpatients,increasedserumceruloplasmin,aregulatorofnitricoxideactivity,isassociatedwith
increasedriskoflong-termadversecardiovascularevents,evenaftermultivariablemodeladjustmentfor
traditionalclinicalandbiologicriskfactors.

Introduction
CKD is a nitric oxide (NO)-deﬁcient state (1), and the
associated oxidative stress contributes to not only the
progression of renal injury, but also its attendant cardiovascular complications (2). NO imbalance can promote inﬂammation, oxidant stress, endothelial
dysfunction, and tissue injury, and it is a potential
contributor to both CKD and cardiovascular disease
progression.
Ceruloplasmin (Cp) is an acute-phase reactant that
is synthesized and secreted by the liver as well as
monocyte/macrophages, and it participates in both
iron and copper metabolism (3). Recently, both antioxidant and pro-oxidant activities of Cp have been
shown and suggest a role for Cp in regulating NO
homeostasis (4). In vitro, Cp shows NO oxidase activity by catalytic consumption of NO, whereas Cp immunodepletion, Cp knockout mice, and humans with
congenital aceruloplasminemia all show diminished
plasma NO oxidase activity (4). Several studies have
also connected Cp levels with increased cardiovascular risk in both the normal population (5 7) and

patients with acute coronary syndromes (8,9). In particular, our group has shown the prognostic value of
elevated Cp, even after adjustment for traditional risk
factors, for determining the future risk of cardiac
events in stable cardiac patients (10).
Despite signiﬁcant evidence that enhanced oxidative and nitrative stresses are present in patients with
CKD and ESRD, the underlying pathways involved in
this imbalance remain a topic of active investigation.
In this study, we sought to establish the possible role
of serum Cp in predicting incident adverse clinical
outcomes, including myocardial infarction (MI),
stroke, and death, among patients with moderate
CKD.

Materials and Methods
Study Population
We performed serum Cp measures in samples
collected from a prospective cohort of 654 successive
individuals with CKD (estimated GFR [eGFR],60
ml/min per 1.73 m2) presenting for elective diagnostic cardiac evaluations at our health system. The

study population was enrolled during 2001 2006; they
were followed prospectively for 3 years (median followup=1095 days), and they consisted of only stable study
participants undergoing elective diagnostic coronary angiography (either cardiac catheterization or coronary computed tomography angiography) not in the setting of
acute coronary syndrome (cardiac troponin I,0.03 mg/L).
Nostudyparticipantswereondialysis.Acontrolgroupof
non-CKD participants (eGFR$60 ml/min per 1.73 m2,
n=250) was obtained from the same setting and matched
for age and sex (1:2.6 versus the CKD group). Venous
bloodsamplescollectedbeforeanyheparinadministration
were obtained in all study participants in serum separator
tubes, processed, aliquoted, and stored at 80°C within
4hoursofcollection.Writteninformedconsentwasobtained
forallstudyparticipants.TheInstitutionalReviewBoardof
theClevelandClinic approvedthe studyprotocols,andthe
studyadhered to theDeclaration ofHelsinki.
Study evaluation included assessment of standard cardiacriskfactors,includingage,sex,systolicBP,andfasting
lipids, as well as history of diabetes mellitus, cigarette
smoking,MI,orheartfailure.eGFRwascalculatedaccording to the four-variable equation of the Kidney Disease
Outcomes Quality Initiative Modiﬁcation of Diet in Renal
Disease study guidelines (11).
End Points
Deﬁnitionofmajoradversecardiovascularevents(MACEs)
included death, nonfatal MI, or nonfatal cerebrovascular
accident.Studystaffascertainedendpointsthroughin-person
follow-up, which included written solicitation and reply
cards,medicalchartreview,anddirect contact.Adjudicated
outcomes were collected for all study participants over the
3-yearfollow-upperiod.
Serum Biochemical Assays
Quantitative measurement of Cp was performed using
an immunoturbidimetric assay (Abbott Architect ci8200;
Abbott, Abbott Park, IL), which yields high-sensitivity
measurementofCplevels.TheCpturbidimetricprocedure
was calibrated at least every 10 days by using multicalibrator material, which was traceable to Reference
Preparation for Protein in Human Serum lot number 91/
0619.DuringoperationoftheAbbottanalyzer,atleasttwo
levels of control material were tested a minimum of one
time per day. The intra-assay coefﬁcient of variation was
3.7%, with an interassay precision of up to 4% over a
referencerangeof20 60mg/dl.Allotherassays,including
high-sensitivity C-reactive protein (CRP), creatinine, and
fasting blood glucose and lipid proﬁles, were measured on
theAbbott Architectplatformas previously described(12).
Statistical Analyses
Continuousvariableswerecomparedusingthettest(for
normal distribution) or Wilcoxon rank sum test (for nonnormal distribution), whereas the chi-squared test was
used for categorical variables. The relationship between
serum Cp levels and other biologic measures was determined by the Spearman correlation. The log-linearity assumptionofCoxmodelswasassessedbyintroductionofa
cubic spline component for each continuous variable.

Receiver operator characteristic curve analyses in the context of the time to event were performed to determine the
optimal cutoff at ,25.5 mg/dl Cp level (which was also
the median Cp level), with a 5-fold cross-validation Cox
model used to estimate risk of event. Using the 5-fold
crossvalidation methods, the data are divided into ﬁve
approximately equally sized portions; the Cox model is
trained on four parts of the data, and then, it estimates
the risk of MACE in the ﬁfth part. This process is repeated
for each of the ﬁve parts, and area under the curve with
the estimated risk is then calculated. This iterative process
was carried out for Cp cutoff values ranging from 19.5 to
34.5 with an increment of 0.1, and the optimal cutoff was
chosen to maximize the C statistics. Quantiﬁcation of
model performance improvement was determined by
both Net Reclassiﬁcation Improvement (NRI) and Integrated Discrimination Improvement, and low-, medium-,
and high-risk category cutoff values for NRI estimation
used a ratio of 6:3:1, respectively. P values represent comparison of models with and without Cp. Models adjustment for established risk factors included age, sex,
smoking, HDL cholesterol, systolic BP, history of diabetes
mellitus, triglyceride, eGFR, serum albumin, and BUN.
Survival curves of the two respective Cp groups (serum
Cp,25.5 versus $25.5 mg/dl) were compared with Kaplan
Meier analysis and the log-rank test. Time-to-event analysis
used to determine hazard ratios (HRs) and 95% conﬁdence
intervals (95% CIs) for MACE was determined by Cox proportional hazards regression, and adjustment was made for
established cardiac risk factors, including age, sex, systolic
BP, cigarette smoking, fasting cholesterol values (including
LDL and HDL cholesterol levels), and eGFR. Additional
adjustments incorporated medication use (including angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, b-blockers, and statin therapy), serum albumin,
BUN, history of MI, and history of heart failure to predict
incident 3-year MACE risks. Statistical signiﬁcance was deﬁned as P,0.05 using SAS version 8.2 (Cary, NC) and
R 2.8.0 (Vienna, Austria).

Results
Subject Characteristics
The baseline characteristics for the study population are
presented in Table 1. For the CKD group, mean and median eGFR were 46613 and 50 ml/min per 1.73 m2 (interquartile range=40 56 ml/min per 1.73 m2), respectively.
Serum Cp in the CKD group was higher compared with
serum Cp in the non-CKD control group (median [interquartile range]; 25.5 [21.8 29.6] versus 22.7 [19.7 26.5]
mg/dl; P,0.001) (Figure 1). Within the CKD group, serum
Cp was correlated with high-sensitivity CRP (r=0.43,
P,0.001), but it did not correlate with indices of renal
function, such as eGFR (r= 0.04, P=0.26) and BUN
(r,0.001, P=0.96).
Serum Cp and Major Adverse Cardiac Outcomes
Within the 3-year follow-up period (median followup=1095 days), a total of 174 events (nonfatal MI, stroke,
or death) was recorded. Dividing Cp as a dichotomous
variable according to the cutoff of 25.5, higher serum Cp
(.25.5 mg/dl) was associated with development of
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serves as a ferroxidase that converts ferrous iron to a
nontoxic ferric iron, thus allowing for its binding to, and
transportby,transferrin.Inthisway,Cpservestoremove
freeferrousironand,thereby,reducesamajorproducerof
superoxide and hydroxyl radical oxidants. Cp can also
serve as a general antioxidant by both catalyzing the destructionofoxygenradicalsaswellasinhibitingtheoxidant
activity of myeloperoxidase (17). Therefore, there may be a
homeostatic balance between pro-oxidant and antioxidant
mechanisms that prevails under different conditions.Inthe
setting of limited NO availability, the NO oxidase function
of Cp might promote nitrative stress and disease progression,whereasinthesettingofexcessiveoxidantproduction,
theantioxidanteffects ofCp may predominate.
The mechanisms leading to the Cp elevations that we
observedinpatients with CKD remain unclear. Tubulointerstitialandglomerularhypoxiaareimportantfactorsthat
accelerate renal disease (18), and recent studies have observed that activation of Cp expression is mechanistically
linked to a hypoxia-inducible factor, where hypoxia response element dependent gene regulation leads to transcriptional induction of the Cp gene promoter (19). These
data,together with the intermittent butrecurringhypoxia
in the setting of CKD (20), suggest that extrinsic factors,
such as hypoxia, may be responsible for modulating Cp
levelsinpatientswithCKD.Furthermore,inaratmodelof
age-associated glomerulosclerosis, caloric restriction preventedelevationsinbothsecretedCpandBowman’s capsule Cp expression and reduced glomerulosclerosis at 24
months(21).ItwasfurthershownthatNF-kBp50bindsto
the kBmotif of Cp expressed inthe parietal epitheliumin
old versus young glomeruli, suggesting an age-associated
NF-kB driven process (22).
Although Cp has established links with measures of
systemicoxidant/nitrativestressandcardiovascularriskin
patientswithnormalrenalfunction(5 10),wenowreport
that serum Cp levels may be prognostically important
within a large cohort of patients with moderate CKD
and prospective long-term clinical event data. Our ﬁndings suggest that Cp may be a potentially important regulator of oxidative and nitrative stress that is increased in
patients with moderately reduced renal function. Because
Cp is readily measured in any clinical chemistry laboratory,itmaybeaclinicallyusefuldiagnosticandtherapeutictargetinthesettingofCKD,becausetreatmentoptions
thataddressthesigniﬁcantburdenofcardiovascularmorbidityandmortalityinthesepatientsarelimited.Ourﬁndings suggest that speciﬁc oxidative and nitrative stress
pathways, such as those pathways catalyzed by Cp, may
beanimportantmodiﬁerofcardiovascularriskinpatients
with moderate CKD, and thus, it is a relevant topic for
future mechanistic investigation.
Study Limitations
Theselectionofstablestage3CKDpatientswithsuspect
coronary disease may introduce a selection bias that potentially confounds interpretation of such case-control
studies. Serum Cp was also only measured at a single
time point, and, as such, we have limited ability to detect
theinﬂuenceoftherapeuticeffectsonCplevelsovertimeor
whetherchangesinCplevelsovertimearealsoofprognostic
importancetopatientswithCKD.Similarly,becausewedo

not have data, such as proteinuria/albuminuria or follow-up
creatinine, on these patients, we are limited in our ability to
fully characterize their underlying renal disease. Because we
do not have complete Cp polymorphism data on these
patients, we are also unable to assess the contribution of
genetic factors in these patients. Despite these limitations, this
study represents the ﬁrst examination, to our knowledge, of
the contribution of Cp to cardiovascular outcomes in a large
cohort of well characterized patients with moderate CKD.
Although such clinical associative studies do not allow a
complete characterization of the etiology of biomarkers, such
as Cp, they do provide an important framework on which
additional mechanistic studies can build. Because patients
with CKD bear a signiﬁcant burden of oxidative and nitrative
stress, as well as cardiovascular morbidity and mortality, our
ﬁndings merit follow-up examination into this potentially
novel oxidative and nitrative stress pathway in CKD.
Elevated Cp levels are associated with increased risk for
development of adverse cardiac events, including nonfatal
MI, nonfatal stroke, or death, in patients with CKD, even
after multivariable models adjustment for established
clinical and biologic risk factors. These ﬁndings are supportive of the hypothesis that oxidative and nitrative stresses
play a signiﬁcant role in mediating cardiac disease progression in CKD and point to the potential pro-oxidant role of
Cp in this setting.
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